VASCULAR AND INTERVENTIONAL RADIOLOGYC olorectal cancer (CRC) is one of the most common malignancies in the world, with metastases to the lungs in approximately 10%-20% of patients (1). Surgery is performed when both the primary tumor and the lung metastases are completely resectable, with a 3-year overall survival (OS) rate of 53%-82% after lung metastasectomy (2-6). Systemic chemotherapy is administered for patients who are not candidates for surgery, but its 3-year OS rate is less than 50% (7,8). Stereotactic radiation therapy is another treatment option for CRC lung metastases but is usually performed in patients who are not candidates for surgery, with a reported 3-year OS rate of 43%-51% (9,10).Radiofrequency ablation (RFA) is another minimally invasive local-regional treatment for malignant lung neoplasms. It has been considered a reasonable alternative to stereotactic radiation therapy, with the advantages of requiring only one treatment procedure, with less cost, and the feasibility of repeat RFA for residual or recurrent tumor (11). The OS rate of RFA for the treatment of CRC lung metastases in patients who are not candidates for surgery is similar to that of stereotactic radiation therapy. In fact, the 3-year OS rates after RFA for colorectal pulmonary metastasis are 46%-57% in prospective studies (12,13) and 46%-76% in retrospective studies (14-16). From Results: Seventy participants with CRC (mean age, 66 years 6 10; 49 men) were evaluated. The 3-year OS rate was 84% (59 of 70 participants; 95% confidence interval [CI]: 76%, 93%). In multivariable analysis, factors associated with worse OS included rectal rather than colon location (hazard ratio [

No abstract

A durable mitral valve repair and preservation of sinus rhythm are the keys to preventing late TR progression.

Since the introduction of transcatheter closure of atrial septal defect, device closure has become the alternative treatment of selected atrial defects. Although excellent results have been reported for transcatheter closure, concerns have arisen regarding complications, including residual shunt, systemic or pulmonary embolization of the device, and erosion and perforation of the cardiac chamber. Those complications are rare but potentially serious adverse events that may require immediate surgical intervention. This review summarizes the current trends in patient selection, result of device closure and typical complications. Comparison between transcatheter device closure and surgical closure is also made.

No abstract